tag:blogger.com,1999:blog-36768584.post7625643423646299417..comments2024-03-03T18:49:34.382-05:00Comments on Omics! Omics!: JPM Wrap-Up: Keith Robisonhttp://www.blogger.com/profile/04765318239070312590noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-36768584.post-48124579751613596362015-01-19T08:32:10.626-05:002015-01-19T08:32:10.626-05:00James: Thanks, but your bitly doesn't seem to ...James: Thanks, but your bitly doesn't seem to quite work -- I believe you are referring to this post <a href="http://core-genomics.blogspot.com/2013/02/genome-partitioning-my-moleculo-esque.html" rel="nofollow">Genome partitioning: my moleculo-esque idea</a>. Your comment on cancer genomes is spot on -- every cancer genome really should be a de novo project. I think you've outlined what is probably how 10X works; I've toyed with the ideas for the last 3 years but without the means to execute on them. GnuBio would have been best positioned to do this & perhaps wishes they went down this path, given they were bought out for only about 2-fold of the funding round for 10X, and this is an easier instrument to build (but at a higher sticker price) than what Gnu was building. That is where it gets tricky; the microfluidic merging of droplets.Keith Robisonhttps://www.blogger.com/profile/04765318239070312590noreply@blogger.comtag:blogger.com,1999:blog-36768584.post-89166634339145415842015-01-19T08:04:24.092-05:002015-01-19T08:04:24.092-05:00Hi Keith, Moleculo-esqu ideas were part of a post ...Hi Keith, Moleculo-esqu ideas were part of a post I wrote around AGBT last year. Other people might come into this space over time if 10X make some headway - and I think there is lots of room for competition.<br /><br />See: http://bit.ly/1J1mbtalJames@cancerhttps://www.blogger.com/profile/02825715598810395734noreply@blogger.com